Literature DB >> 27995312

Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up.

Thomas Kurt Eigentler1, Joachim Hinderer2, Seema Noor3, Claus Garbe3, Ulrike Leiter3.   

Abstract

BACKGROUND: Sentinel node (SN) biopsy is regarded as standard of care for patients (pts) with cutaneous melanoma ≥1.0 mm of thickness. In the recent AJCC classification, findings in the SN are simply classified as positive or negative. In our analyses, we were interested whether quantitative real-time PCR (qRT-PCR) is able to predict disease-free survival (DFS) and overall survival (OS) depending on tumour burden in the SN.
METHODS: One hundred and forty-five pts were analysed using qRT-PCR for tyrosinase. Results were analysed using accelerated failure time survival model and cox proportional hazards models using the R statistics framework.
RESULTS: Forty-one pts (28%) were positive according to qRT-PCR. In total, 12 of 41 pts showed tumour deposits in the SN using S100 and/or HMB-45-labelled immunohistochemistry as well. One patient had micrometastases detected by immunohistochemistry staining but failed in the qRT-PCR. After 10 years of follow-up, 34 patients recurred and 27 patients died. Significant differences for DFS and OS were detected for sex, increasing tumour thickness, ulceration of the primary tumour, and metastatic spread in the SN determined by histology as well as qRT-PCR.
CONCLUSION: Quantitative analyses showed a logarithmic correlation between tumour burden and prognosis. However, as multivariate analyses reveal qRT-PCR was not superior compared to classical histology or immunohistology.

Entities:  

Keywords:  Cutaneous melanoma; Prognosis; Quantitative real-time PCR; Sentinel node biopsy

Mesh:

Year:  2016        PMID: 27995312     DOI: 10.1007/s00432-016-2323-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  11 in total

1.  Quantitative real-time RT-PCR in sentinel lymph nodes from melanoma patients. Detection of melanocytic mRNA predicts disease-free survival.

Authors:  Rikke Riber-Hansen; Helene Nortvig Abrahamsen; Boe Sandahl Sorensen; Stephen Jacques Hamilton-Dutoit; Torben Steiniche
Journal:  APMIS       Date:  2008-03       Impact factor: 3.205

2.  Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.

Authors:  Ulrike Leiter; Rudolf Stadler; Cornelia Mauch; Werner Hohenberger; Norbert Brockmeyer; Carola Berking; Cord Sunderkötter; Martin Kaatz; Klaus-Werner Schulte; Percy Lehmann; Thomas Vogt; Jens Ulrich; Rudolf Herbst; Wolfgang Gehring; Jan-Christoph Simon; Ulrike Keim; Peter Martus; Claus Garbe
Journal:  Lancet Oncol       Date:  2016-05-05       Impact factor: 41.316

3.  Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma.

Authors:  H J Blaheta; U Ellwanger; B Schittek; K Sotlar; E MacZey; H Breuninger; M H Thelen; B Bueltmann; G Rassner; C Garbe
Journal:  J Invest Dermatol       Date:  2000-04       Impact factor: 8.551

4.  Technical details of intraoperative lymphatic mapping for early stage melanoma.

Authors:  D L Morton; D R Wen; J H Wong; J S Economou; L A Cagle; F K Storm; L J Foshag; A J Cochran
Journal:  Arch Surg       Date:  1992-04

5.  Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?

Authors:  A C J van Akkooi; J H W de Wilt; C Verhoef; P I M Schmitz; A N van Geel; A M M Eggermont; M Kliffen
Journal:  Ann Oncol       Date:  2006-09-12       Impact factor: 32.976

6.  A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma.

Authors:  H Starz; B R Balda; K U Krämer; H Büchels; H Wang
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

7.  RT-PCR analysis of RNA extracted from Bouin-fixed and paraffin-embedded lymphoid tissues.

Authors:  Annunziata Gloghini; Barbara Canal; Ulf Klein; Luigino Dal Maso; Tiziana Perin; Riccardo Dalla-Favera; Antonino Carbone
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

8.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Authors:  Alexander M M Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena Musat; Alain Spatz; Ulrich Keilholz
Journal:  Lancet       Date:  2008-07-12       Impact factor: 79.321

9.  Tyrosinase RT-PCR as a supplement to histology for detecting melanoma and nevus cells in paraffin sections of sentinel lymph nodes.

Authors:  Hans Starz; Christian J Haas; Gesa-Maria Schulz; Bernd-Rüdiger Balda
Journal:  Mod Pathol       Date:  2003-09       Impact factor: 7.842

10.  Quantitative measurement of melanoma spread in sentinel lymph nodes and survival.

Authors:  Anja Ulmer; Klaus Dietz; Isabelle Hodak; Bernhard Polzer; Sebastian Scheitler; Murat Yildiz; Zbigniew Czyz; Petra Lehnert; Tanja Fehm; Christian Hafner; Stefan Schanz; Martin Röcken; Claus Garbe; Helmut Breuninger; Gerhard Fierlbeck; Christoph A Klein
Journal:  PLoS Med       Date:  2014-02-18       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.